Aptadir Therapeutics raises €40M ($45M) in Seed financing to advance first-in-class demethylating medicines, led by 4BIO Capital.
Amount Raised
$45 Million
Round Type
Seed
MilanBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Aptadir Therapeutics has closed its €40M Seed round to develop RNA inhibitor-based therapeutics. The funding was led by 4BIO Capital and includes follow-on participation from original investors. The funds will advance the company's pipeline for treating genetic conditions. Aptadir's technology targets gene silencing and aims to restore normal biological functions.
Quick answer
Aptadir Therapeutics raised $45 Million in a Seed round, dated September 29, 2026. Investors: Evotec SE, XGEN Venture, Ce Ventures, Kerna Ventures, Club Degli Investitori, Indaco Venture Partners, 4BIO Capital and CDP Venture Capital. Aptadir Therapeutics is based in Milan, Lombardy, Italy.
- How much did Aptadir Therapeutics raise?
- Aptadir Therapeutics raised $45 Million in a Seed round on September 29, 2026.
- Who invested in Aptadir Therapeutics?
- Evotec SE, XGEN Venture, Ce Ventures, Kerna Ventures, Club Degli Investitori, Indaco Venture Partners, 4BIO Capital and CDP Venture Capital are named as investors in this round.
- What does Aptadir Therapeutics do?
- Aptadir Therapeutics is a preclinical biotech company developing a new class of RNA therapeutics.
- Where is Aptadir Therapeutics based and how big is it?
- Aptadir Therapeutics is based in Milan, Lombardy, Italy. Fundz records about 4 employees.
- Who are the decision-makers at Aptadir Therapeutics?
- Fundz holds 1 contact at Aptadir Therapeutics, including the Founder, Executive Chairman and CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Aptadir Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- VolitionRx raised $2.4M (Convertible Note) on October 27, 2026.
- Estuary Biotherapeutics raised $93M (Series A) on October 16, 2026.
- seragy holding GmbH raised $13M on October 14, 2026.
- Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
Who to call at Aptadir Therapeutics, and when
A new round usually means Aptadir Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aptadir Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aptadir Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aptadir Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aptadir Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Aptadir Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.